This episode discusses a huge unmet need in the medical device space: treatment for mixed urinary incontinence. Millions of patients, primarily women, suffer from this condition, and there is no effective treatment on the market. Current treatment options leave care gaps and patients resorting to over-the-counter products for symptom management.

Juniper Biomedical is a company that is developing a new type of treatment for mixed urinary incontinence. They are developing a unique neuromodulation micro implant that can be implanted with a minimally invasive procedure to deliver a very precise therapy. This has the potential to solve the problems of mixed incontinence, eliminate issues with inaccurate diagnosis, and importantly, provide a solution that patients are more likely to accept.

CEO and co-founder, David Constantine joins us to discuss their exciting progress, from extensive preclinical studies, to upcoming clinical trials. After a year of multiple highlights, including award winning on the stage of Medtech Innovator, the future looks bright for Juniper Biomedical. Their technology has the potential to make a real difference in the lives of millions of patients with pelvic health conditions, a story sure to leave you, informed and inspired.